Effects of substance P and somatostatin on taurocholate-stabilized and CCK- or secretin-induced choleresis in the anesthetized dog.
Eleven anesthetized dogs were provided with a common bile duct fistula, and the gallbladder was excluded. After stabilization of the bile flow by intravenous infusions of taurocholate, various peptides were administered intravenously. Substance P (SP) decreased the output of hepatic bile, bile acids, sodium, potassium, and bicarbonate by about 50%. When SP was superimposed on cholecystokinin (CCK)- or secretin-induced choleresis, all CCK-induced effects were abolished, whereas SP had a less pronounced anticholeretic effect when choleresis was induced by secretin. Somatostatin (SST) decreased the output of hepatic bile, bile acids, sodium, potassium, and bicarbonate by about 25%. SST had no inhibitory effect on CCK- or secretin-induced choleresis. It is suggested that the principal mode of action of SST on bile flow is indirect by inhibiting the release of choleretic hormones, whereas SP is suggested to act directly on the hepatocytes.
D000818:Animals; D001639:Bicarbonates / Q000032:analysis; D001646:Bile / Q000032:analysis / Q000378:metabolism*; D001647:Bile Acids and Salts / Q000032:analysis; D002766:Cholecystokinin / Q000494:pharmacology*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005260:Female; D006863:Hydrogen-Ion Concentration; D007263:Infusions, Parenteral; D008297:Male; D011188:Potassium / Q000032:analysis; D012633:Secretin / Q000494:pharmacology*; D012964:Sodium / Q000032:analysis; D013004:Somatostatin / Q000494:pharmacology*; D013373:Substance P / Q000494:pharmacology*; D013656:Taurocholic Acid / Q000494:pharmacology*
D001639:Bicarbonates; D001647:Bile Acids and Salts; D012633:Secretin; D013373:Substance P; D013004:Somatostatin; D013656:Taurocholic Acid; D002766:Cholecystokinin; D012964:Sodium; D011188:Potassium